Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis

[1]  Hirotaka Chikuda,et al.  Perioperative stroke in patients undergoing elective spinal surgery: a retrospective analysis using the Japanese diagnosis procedure combination database , 2015, BMC Musculoskeletal Disorders.

[2]  S. Xiao,et al.  Evaluation of the Aspartate Aminotransferase/Platelet Ratio Index and Enhanced Liver Fibrosis Tests to Detect Significant Fibrosis Due to Chronic Hepatitis C , 2014, Journal of clinical gastroenterology.

[3]  J. Fallowfield,et al.  Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. , 2014, Journal of hepatology.

[4]  T. Saibara,et al.  Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients , 2014, Journal of Gastroenterology.

[5]  M. Abrahamowicz,et al.  Profile of the Risk of Death After Septic Shock in the Present Era: An Epidemiologic Study , 2013, Critical care medicine.

[6]  L. Baddour,et al.  Predictive scoring model of mortality in Gram-negative bloodstream infection. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  G. Zararsiz,et al.  Noninvasive assessment of liver damage in chronic hepatitis B. , 2013, World journal of hepatology.

[8]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification , 2013, Journal of Clinical Pathology.

[9]  Hirotaka Chikuda,et al.  Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database , 2013, BMJ Open.

[10]  M. Gönen,et al.  Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. , 2013, Journal of the American College of Surgeons.

[11]  P. Gill,et al.  Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. , 2013, Journal of hepatology.

[12]  W. Kratzer,et al.  Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years , 2012, BMC Gastroenterology.

[13]  A. Tsung,et al.  Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: A case‐control study , 2012, Hepatology.

[14]  N. Chalasani,et al.  Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .

[15]  Robert D. Goldin,et al.  The epidemiology, pathogenesis and histopathology of fatty liver disease , 2012, Histopathology.

[16]  A. Diehl,et al.  Mechanisms of disease progression in NASH: new paradigms. , 2012, Clinics in liver disease.

[17]  H. Ferral,et al.  Transjugular Liver Biopsy , 2012, Seminars in Interventional Radiology.

[18]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[19]  T. Saibara,et al.  Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population , 2011, BMC Gastroenterology.

[20]  A. Szymczak,et al.  Safety and Effectiveness of Blind Percutaneous Liver Biopsy: Analysis of 1412 Procedures , 2012, Hepatitis monthly.

[21]  J. Rhee,et al.  Liver cirrhosis as a risk factor for mortality in a national cohort of patients with bacteremia. , 2011, The Journal of infection.

[22]  Ned C. Rouze,et al.  Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[23]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[24]  K. Brundyn,et al.  APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. , 2011, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[25]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[27]  M. Krawczyk,et al.  Nonalcoholic fatty liver disease. , 2010, Best practice & research. Clinical gastroenterology.

[28]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[29]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[30]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[31]  F. Schick,et al.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.

[32]  J. Vauthey,et al.  Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. , 2009, The Lancet. Oncology.

[33]  M. Michael,et al.  Part II: Liver function in oncology: towards safer chemotherapy use. , 2008, The Lancet. Oncology.

[34]  M. Michael,et al.  Part I: Liver function in oncology: biochemistry and beyond. , 2008, The Lancet. Oncology.

[35]  A. Loaeza-del-Castillo,et al.  AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. , 2008, Annals of hepatology.

[36]  A. Shahrokni,et al.  Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. , 2007, JOP : Journal of the pancreas.

[37]  M. Choti,et al.  Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome , 2007, Journal of Gastrointestinal Surgery.

[38]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  M. Schiff,et al.  CASE REPORT: Fatal Cholestatic Liver Failure Associated with Gemcitabine Therapy , 2003, Digestive Diseases and Sciences.

[41]  D. Mannino,et al.  Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. , 2003, Chest.

[42]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[43]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[44]  R. Wiesner,et al.  Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. , 2002 .

[45]  M. Perry,et al.  Hepatotoxicity of chemotherapy. , 2001, Expert opinion on drug safety.

[46]  R. Reznek,et al.  Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. , 1998, British Journal of Cancer.

[47]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[48]  Jones Sf,et al.  Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.

[49]  C. Fenger,et al.  Reversible hepatic steatosis in patients treated with interferon alfa‐2A and 5‐fluorouracil , 1995, Cancer.

[50]  J. Beijnen,et al.  Taxanes: a new class of antitumor agents. , 1995, Cancer investigation.

[51]  J. Verweij,et al.  Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.

[52]  T. Fleming,et al.  Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  F. Carnot,et al.  Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. , 1991, Journal of hepatology.

[54]  J. Goldberg,et al.  Cyclophosphamide-associated hepatotoxicity. , 1985, Southern medical journal.

[55]  A. Avilés,et al.  Hepatic injury during doxorubicin therapy. , 1984, Archives of pathology & laboratory medicine.

[56]  D. Johnson,et al.  Etoposide-induced hepatic injury: a potential complication of high-dose therapy. , 1983, Cancer treatment reports.

[57]  N. Hill,et al.  Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. , 1975, Cancer chemotherapy reports.